Company news
Biofrontera Inc. (NASDAQ:BFRI) news
Every Biofrontera Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
September 14, 2026
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
August 13, 2026
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
August 5, 2026
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 21, 2026
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
May 14, 2026
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
May 13, 2026
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
May 8, 2026
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
March 19, 2026
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe ...
March 9, 2026
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe ...
March 9, 2026
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
February 26, 2026
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
February 17, 2026
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
February 11, 2026
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting...
February 9, 2026
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approxim...
January 13, 2026
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
January 8, 2026
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
December 18, 2025
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extrem...
December 4, 2025
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC...
December 2, 2025
Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update
November 13, 2025
Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M
November 7, 2025
Biofrontera Inc. to Report Third Quarter 2025 Financial Results on November 12, 2025 and Host a Conference Call on November 13, 2025
November 6, 2025
Biofrontera Inc. Closes Purchase of All Ameluz® and RhodoLED® US Assets from Biofrontera AG
October 23, 2025
Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 26, 2025
Biofrontera Inc. Engages Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program
September 23, 2025
Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (...
September 16, 2025
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of ...
August 25, 2025
Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update
August 13, 2025
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
August 11, 2025
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
August 4, 2025
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
June 30, 2025
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
June 11, 2025
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in F...
June 3, 2025
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
May 15, 2025
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Amel...
May 15, 2025
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
May 6, 2025
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis
May 1, 2025
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update
March 21, 2025
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for th...
March 18, 2025
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025
March 11, 2025
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superf...
January 8, 2025
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
December 23, 2024
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
November 22, 2024
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
November 13, 2024
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
November 1, 2024
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of S...
October 31, 2024
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cel...
October 14, 2024
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
October 7, 2024
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 14, 2024
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
June 24, 2024